Sustained rise in antimicrobial resistance in India: ICMR study

  10 September 2022

A big chunk of patients in India may no longer benefit from carbapenem, a powerful antibiotic administered mainly in ICU settings to treat pneumonia and septicemia, as they have developed antimicrobial resistance to it, an ICMR study has found.

The data analysis done between January 1 and December 31, 2021, pointed towards a sustained increase in drug-resistant pathogens, resulting in difficulty to treat certain infections with available medicines, senior Indian Council of Medical Research (ICMR) scientist Dr. Kamini Walia, who led the study, said.

Further reading: Teh Hindu
Author(s): The Hindu
Effective Surveillance  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!